DOCSLIB.ORG

Drug Discovery for Kinetoplastid Diseases: Future Directions † ‡ § ∥ Srinivasa P

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug Discovery for Kinetoplastid Diseases: Future Directions † ‡ § ∥ Srinivasa P This is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes. Viewpoint Cite This: ACS Infect. Dis. XXXX, XXX, XXX−XXX pubs.acs.org/journal/aidcbc Drug Discovery for Kinetoplastid Diseases: Future Directions † ‡ § ∥ Srinivasa P. S. Rao,*, Michael P. Barrett, Glenn Dranoff, Christopher J. Faraday, ⊥ # † ∇ ° Claudio R. Gimpelewicz, Asrat Hailu, Catherine L. Jones, John M. Kelly, Janis K. Lazdins-Helds, • ¶ × Pascal Maser,̈ Jose Mengel,$,@ Jeremy C. Mottram,+ Charles E. Mowbray, David L. Sacks, ∼ † † Phillip Scott,& Gerald F. Spath,̈ ^ Rick L. Tarleton, Jonathan M. Spector, and Thierry T. Diagana*, † Novartis Institute for Tropical Diseases (NITD), 5300 Chiron Way, Emeryville, California 94608, United States ‡ University of Glasgow, University Place, Glasgow G12 8TA, United Kingdom § Immuno-oncology, Novartis Institutes for Biomedical Research (NIBR), 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States ∥ Autoimmunity, Transplantation and Inflammation, NIBR, Fabrikstrasse 2, CH-4056 Basel, Switzerland ⊥ Global Drug Development, Novartis Pharma, Forum 1, CH-4056 Basel, Switzerland # School of Medicine, Addis Ababa University, P.O. Box 28017 code 1000, Addis Ababa, Ethiopia ∇ London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom ° Independent Consultant, Chemic Des Tulipiers 9, 1208 Geneva, Switzerland • Swiss Tropical and Public Health Institute, Socinstrasse 57, 4501 Basel, Switzerland; University of Basel, CH 4000 Basel, Switzerland $Laboratory of Clinical Immunology, Oswaldo Cruz Institute, FIOCRUZ-RJ, Av. Brasil 4365, Cep: 21040-900, Rio de Janeiro-RJ, Brazil @Faculty of Medicine of Petropolis, University in Petropolis,̀ Av. Barao do Rio Branco 1003, Cep: 25680-120, Petropolis-RJ, Brazil +University of York, Wentworth Way Heslington, York YO10 5DD, United Kingdom ¶ Drugs for Neglected Diseases initiative, 15 Chemin Louis-Dunant, 1202 Geneva, Switzerland × National Institute of Allergy and Infectious Diseases, 4 Memorial Drive, Bethesda, Maryland 20892, United States &University of Pennsylvania, 380 South University Avenue, Philadelphia, Pennsylvania 19104, United States ^Institut Pasteur, 25 Rue du Docteur Roux, 75015 Paris, France ∼ University of Georgia, Coverdell Center, 500 DW Brooks Dr, Athens, Georgia 30602, United States ABSTRACT: Kinetoplastid parasites have caused human disease for millennia. Significant achievements have been made toward developing new treatments for leishmaniasis (particularly on the Indian subcontinent) and for human African trypanosomiasis (HAT). Moreover, the sustained decrease in the incidence of HAT has made the prospect of elimination a Downloaded via 188.63.101.230 on January 22, 2019 at 09:16:45 (UTC). tantalizing reality. Despite the gains, no new chemical or biological entities to treat kinetoplastid diseases have been registered in more than three decades, and more work is needed to discover safe and effective therapies for patients with Chagas disease and leishmaniasis. Advances in tools for drug discovery and novel insights into the biology of the host−parasite interaction may provide opportunities for accelerated progress. Here, we summarize the output from a gathering of scientists and physicians who See https://pubs.acs.org/sharingguidelines for options on how to legitimately share published articles. met to discuss the current status and future directions in drug discovery for kinetoplastid diseases. early a billion people are at risk from the group of vector- Neglected Diseases initiative (DNDi) directing global efforts N borne kinetoplastid diseases comprised of Chagas for new therapies. The introduction of nifurtimox-eflornithine disease, leishmaniasis, and human African trypanosomiasis therapy in 2009 was a pivotal milestone, which was followed (HAT, also known as sleeping sickness). These ancient recently by the demonstrated efficacy of oral fexinidazole2 for parasitic illnesses have burdened humans for thousands of late-stage disease. (Approval for use is now pending assessment years, as evidenced by Trypanosoma DNA sequences found in by medicine regulatory agencies.) Fewer than 1500 new cases South American mummies.1 In the current era, kinetoplastid were reported to WHO in 2017, making disease elimination a diseases cause an estimated 30 000 deaths annually and induce tangible goal. crippling morbidities in millions more. Successes in combating HAT are encouraging and contrast There is reason to be optimistic about trends concerning with slower progress in containing other kinetoplastid diseases. HAT. Public and private partners have jointly tackled the disease in recent decades, with the World Health Organization Received: November 1, 2018 (WHO) coordinating public health activities and the Drugs for © XXXX American Chemical Society A DOI: 10.1021/acsinfecdis.8b00298 ACS Infect. Dis. XXXX, XXX, XXX−XXX ACS Infectious Diseases Viewpoint Figure 1. Clinical manifestations of kinetoplastid diseases and opportunities for intervention. Most of the current kinetoplastid drugs are repurposed and are 15−30% patients are unable to finish the standard 60-day often not potent enough to render a sterile cure (i.e., to course, mainly because of skin and nervous system eliminate all parasites). Safe, effective, short-course practical complications. In children, nifurtimox is better tolerated than therapies are urgently needed for Chagas disease and benznidazole. leishmaniasis yet remain elusive. In both acute and chronic T. cruzi infection, treatment To understand the present-day challenges and opportunities reduces the parasite load and can yield clearance from blood related to new medicines for Chagas disease, visceral using available assays (e.g., PCR). Even so, in some cases, leishmaniasis (VL), and cutaneous leishmaniasis (CL), the parasites presumably may persist intracellularly, and it is Novartis Institute for Tropical Diseases convened a multi- unclear in adults how the reductions in the parasite load disciplinary group of scientific and medical specialists in modulate the severity of chronic disease in the absence of parasitology, immunology, and drug discovery in June 2018. complete parasite clearance. Current drugs are inadequate The scope of the discussion encompassed unmet medical because they fail too often and are not dependable. However, needs, the global pipeline of preclinical drug candidates, WHO recommends off-label use of benznidazole for the parasite biology, assays, models, and the potential use of novel treatment of chronically infected patients, even though its immunomodulatory and adjunct therapies to target disease efficacy in later stages of the disease is debatable. A large study sequelae. This Viewpoint summarizes key workshop learnings. of patients with chronic Chagas cardiomyopathy (the BENEFIT trial) demonstrated that benznidazole treatment ■ CURRENT DRUGS: OLD, TOXIC, AND OFTEN reduced the parasite burden but did not significantly reduce INEFFECTIVE disease progression. However, most subjects had New York Chagas disease, which is endemic in the Americas, is caused by Heart Association class I (largely asymptomatic) heart disease, Trypanosoma cruzi. Inoculation typically occurs through which may have confounded the findings.3 Some non- infected feces from the triatomine bug, which is scratched or randomized, unblinded studies using benznidazole in inde- rubbed into the skin or mucosa. Transmission also takes place terminate patients without heart failure showed reduced through blood transfusion and congenital and oral routes. The disease progression, emphasizing the need for controlled pathogenesis of Chagas disease is not fully understood, and it is randomized studies for indeterminate patients.4 currently impossible to predict which fraction of the patient Similarly, the approved therapeutic arsenal for leishmaniasis population (approximately 30%) will develop the serious has important limitations. Leishmaniasis is distributed across cardiac or gastrointestinal sequelae that appear years after the the tropics and subtropics, though a majority of VL cases are initial infection (Figure 1). Sudden death from chronic Chagas reported in only seven countries: Brazil, Ethiopia, Kenya, cardiomyopathy is an all too common outcome. Two drugs, Somalia, Sudan, South Sudan, and India. Patients succumb to nitroheterocyclic agents benznidazole and nifurtimox, are used VL gradually over a period of 2 years. Anorexia and for the treatment of Chagas disease; both were developed pancytopenia give rise to wasting and increased susceptibility decades ago, are contraindicated during pregnancy, and can to bacterial superinfections. VL is fatal without treatment, and have serious adverse effects that substantially restrict their use. even those who undergo therapy remain at risk of a disfiguring Benznidazole is the better-tolerated option in adults, although dermal form of relapsing disease called post kala-azar dermal B DOI: 10.1021/acsinfecdis.8b00298 ACS Infect. Dis. XXXX, XXX, XXX−XXX ACS Infectious Diseases Viewpoint leishmaniasis (PKDL) that may also contribute to continued disease transmission (Figure 1). CL has a higher global burden than VL, with the greatest prevalence in Africa, the Mediterranean, and South America. It does not cause systemic morbidities or death but can result in grievous disfiguration and stigma. Drugs targeting Leishmania parasites have generally been repurposed from other indications.
Load more

Recommended publications
  • 2018 Guideline Document on Chagas Disease
    GUIDELINES AND STANDARDS Recommendations for Multimodality Cardiac Imaging in Patients with Chagas Disease: A Report from the American Society of Echocardiography in Collaboration With the InterAmerican Association of Echocardiography (ECOSIAC) and the Cardiovascular Imaging Department of the Brazilian Society of Cardiology (DIC-SBC) Harry Acquatella, MD, FASE (Chair), Federico M. Asch, MD, FASE (Co-Chair), Marcia M. Barbosa, MD, PhD, FASE, Marcio Barros, MD, PhD, Caryn Bern, MD, MPH, Joao L. Cavalcante, MD, FASE, Luis Eduardo Echeverria Correa, MD, Joao Lima, MD, Rachel Marcus, MD, Jose Antonio Marin-Neto, MD, PhD, Ricardo Migliore, MD, PhD, Jose Milei, MD, PhD, Carlos A. Morillo, MD, Maria Carmo Pereira Nunes, MD, PhD, Marcelo Luiz Campos Vieira, MD, PhD, and Rodolfo Viotti, MD*, Caracas, Venezuela; Washington, District of Columbia; Belo Horizonte and Sao~ Paulo, Brazil; San Francisco, California; Pittsburgh, Pennsylvania; Floridablanca, Colombia; Baltimore, Maryland; San Martin and Buenos Aires, Argentina; and Hamilton, Ontario, Canada In addition to the collaborating societies listed in the title, this document is endorsed by the following American Society of Echocardiography International Alliance Partners: the Argentinian Federation of Cardiology, the Argentinian Society of Cardiology, the British Society of Echocardiography, the Chinese Society of Echocardiography, the Echocardiography Section of the Cuban Society of Cardiology, the Echocardiography Section of the Venezuelan Society of Cardiology, the Indian Academy of Echocardiography,
    [Show full text]
  • Chagas Disease Fact Sheet
    Chagas Disease Fact Sheet What is Chagas disease? What are the symptoms? ■ A disease that can cause serious heart and stomach ■ A few weeks or months after people first get bitten, illnesses they may have mild symptoms like: ■ A disease spread by contact with an infected • Fever and body aches triatomine bug also called “kissing bug,” “benchuca,” • Swelling of the eyelid “vinchuca,” “chinche,” or “barbeiro” • Swelling at the bite mark ■ After this first part of the illness, most people have no Who can get Chagas disease? symptoms and many don’t ever get sick Anyone. However, people have a greater chance if they: ■ But some people (less than half) do get sick later, and they may have: ■ Have lived in rural areas of Mexico, Central America or South America, in countries such as: Argentina, • Irregular heart beats that can cause sudden death Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, • An enlarged heart that doesn’t pump blood well El Salvador, Ecuador, French Guiana, Guatemala, • Problems with digestion and bowel movements Guyana, Honduras, Mexico, Nicaragua, Panama, • An increased chance of having a stroke Paraguay, Peru, Suriname, Uruguay or Venezuela What should I do if I think I might have ■ Have seen the bug, especially in these areas Chagas disease? ■ Have stayed in a house with a thatched roof or with ■ See a healthcare provider, who will examine you walls that have cracks or crevices ■ Your provider may take a sample of your blood for testing How does someone get Chagas disease? ■ Usually from contact with a kissing bug Why should I get tested for Chagas disease? ■ After the kissing bug bites, it poops.
    [Show full text]
  • Zoonotic Disease Scenarios
    Zoonotic Disease Scenarios: Malaria, Arboviruses, Chagas Disease, Lyme Disease, and Rickettsial Diseases ELC Meeting – September 2019 Zoonosis Control Branch Malaria Case Scenario A new ELR appears in the DRR queue for a blood smear, with a positive result for malaria. Resiu l~edl Test: MICROSCOPIC OBSERVATION:PRIO:PT:BLO:NOMl :MAL.ARIA SMIEAR(Mala 11ia S nnear) Result(st: Posimive(S I OMED) Refelrence Range: 1 eg1ative Datem ime: 2019-IJ2-0'9 12:09:IJO .O , ·erpreta~iio 111 : Nlormal Perilforming Faciility: University Med C r Result Method: IFaciility ID: 5D06607 4'1 (Fl) Status: f inal "[;est Code(s): 32700-7 (LIN LOINC) 1278 (L l OCAL) !Result Code(s): '1O B281J04 (SNM SNOMED) I R.es u It Comm e111ts: 09/26/2019 DSHS ELC Conference 2 Malaria Case Scenario (continued) The species has not been determined yet. Upon reviewing the medical record, you learn that the patient is a 62-year-old female who is a resident of Nigeria and returning home next month. Q: Is this a reportable Texas malaria case? YES! 09/26/2019 DSHS ELC Conference 3 Malaria Reporting Guidelines Texas Residents For malaria cases who reside in Texas, but are diagnosed in another Texas jurisdiction, please report by the case patient’s residence. Out of Country Residents For malaria cases who reside in another country, but are diagnosed in Texas, please report by the location where the patient was diagnosed. Out of State Residents For malaria cases who reside in another state, but are diagnosed in Texas, please communicate with the Regional Zoonosis Control (ZC) office so we can work with the other state to determine which state will count it as a case to prevent dual reporting.
    [Show full text]
  • Leishmaniasis in the United States: Emerging Issues in a Region of Low Endemicity
    microorganisms Review Leishmaniasis in the United States: Emerging Issues in a Region of Low Endemicity John M. Curtin 1,2,* and Naomi E. Aronson 2 1 Infectious Diseases Service, Walter Reed National Military Medical Center, Bethesda, MD 20814, USA 2 Infectious Diseases Division, Uniformed Services University, Bethesda, MD 20814, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-011-301-295-6400 Abstract: Leishmaniasis, a chronic and persistent intracellular protozoal infection caused by many different species within the genus Leishmania, is an unfamiliar disease to most North American providers. Clinical presentations may include asymptomatic and symptomatic visceral leishmaniasis (so-called Kala-azar), as well as cutaneous or mucosal disease. Although cutaneous leishmaniasis (caused by Leishmania mexicana in the United States) is endemic in some southwest states, other causes for concern include reactivation of imported visceral leishmaniasis remotely in time from the initial infection, and the possible long-term complications of chronic inflammation from asymptomatic infection. Climate change, the identification of competent vectors and reservoirs, a highly mobile populace, significant population groups with proven exposure history, HIV, and widespread use of immunosuppressive medications and organ transplant all create the potential for increased frequency of leishmaniasis in the U.S. Together, these factors could contribute to leishmaniasis emerging as a health threat in the U.S., including the possibility of sustained autochthonous spread of newly introduced visceral disease. We summarize recent data examining the epidemiology and major risk factors for acquisition of cutaneous and visceral leishmaniasis, with a special focus on Citation: Curtin, J.M.; Aronson, N.E.
    [Show full text]
  • Drugs for Amebiais, Giardiasis, Trichomoniasis & Leishmaniasis
    Antiprotozoal drugs Drugs for amebiasis, giardiasis, trichomoniasis & leishmaniasis Edited by: H. Mirkhani, Pharm D, Ph D Dept. Pharmacology Shiraz University of Medical Sciences Contents Amebiasis, giardiasis and trichomoniasis ........................................................................................................... 2 Metronidazole ..................................................................................................................................................... 2 Iodoquinol ........................................................................................................................................................... 2 Paromomycin ...................................................................................................................................................... 3 Mechanism of Action ...................................................................................................................................... 3 Antimicrobial effects; therapeutics uses ......................................................................................................... 3 Leishmaniasis ...................................................................................................................................................... 4 Antimonial agents ............................................................................................................................................... 5 Mechanism of action and drug resistance ......................................................................................................
    [Show full text]
  • Visceral Leishmaniasis: a Global Overview
    J Glob Health Sci. 2020 Jun;2(1):e3 https://doi.org/10.35500/jghs.2020.2.e3 pISSN 2671-6925·eISSN 2671-6933 Review Article Visceral leishmaniasis: a global overview Richard G. Wamai ,1 Jorja Kahn ,2 Jamie McGloin ,3 Galen Ziaggi 3 1Department of Cultures, Societies and Global Studies, Northeastern University, College of Social Sciences and Humanities, Integrated Initiative for Global Health, Boston, MA, USA 2Department of Behavioral Neuroscience, Northeastern University, College of Science, Boston, MA, USA 3Department of Health Sciences, Northeastern University, Bouvé College of Health Science, Boston, MA, USA Received: Feb 1, 2020 ABSTRACT Accepted: Mar 14, 2020 Correspondence to The leishmaniases are protozoan infections that are among the neglected tropical diseases Richard G. Wamai (NTDs). Over one billion people are at risk of these diseases in virtually all continents. Department of Cultures, Societies and Global These diseases debilitate large numbers of people, keeping them from full, productive lives. Studies, Northeastern University, College of Visceral leishmaniasis (VL) is the most severe form of these diseases, killing more people Social Sciences and Humanities, Integrated Initiative for Global Health, 360 Huntington than any other parasitic disease except malaria. About 90% of the global burden for VL is Ave., Boston, MA 02115, USA. found in just 7 countries, 4 of which are in Eastern Africa (Sudan, South Sudan, Ethiopia E-mail: [email protected] and Kenya), 2 in Southeast Asia (India, Bangladesh) and Brazil, which carries nearly all of cases in South America. In 2005 the World Health Organization launched a strategy to © 2020 Korean Society of Global Health.
    [Show full text]
  • Guidelines for Diagnosis, Treatment and Prevention of Visceral Leishmaniasis in South Sudan
    Guidelines for diagnosis, treatment and prevention of visceral leishmaniasis in South Sudan Acromyns DAT Direct agglutination test FDA Freeze – dried antigen IM Intramuscular IV Intravenous KA Kala–azar ME Mercaptoethanol ORS Oral rehydration salt PKDL Post kala–azar dermal leishmaniasis RBC Red blood cells RDT Rapid diagnostic test RR Respiratory rate SSG Sodium stibogluconate TFC Therapeutic feeding centre TOC Test of cure VL Visceral leishmaniasis WBC White blood cells WHO World Health Organization Table of contents Acronyms ...................................................................................................................................... 2 Acknowledgements ....................................................................................................................... 4 Foreword ...................................................................................................................................... 5 1. Introduction ........................................................................................................................... 7 1.1 Background information ............................................................................................... 7 1.2 Lifecycle and transmission patterns ............................................................................. 7 1.3 Human infection and disease ....................................................................................... 8 2. Diagnosis ..............................................................................................................................
    [Show full text]
  • Louisiana Morbidity Report
    Louisiana Morbidity Report Office of Public Health - Infectious Disease Epidemiology Section P.O. Box 60630, New Orleans, LA 70160 - Phone: (504) 568-8313 www.dhh.louisiana.gov/LMR Infectious Disease Epidemiology Main Webpage BOBBY JINDAL KATHY KLIEBERT GOVERNOR www.infectiousdisease.dhh.louisiana.gov SECRETARY September - October, 2015 Volume 26, Number 5 Cutaneous Leishmaniasis - An Emerging Imported Infection Louisiana, 2015 Benjamin Munley, MPH; Angie Orellana, MPH; Christine Scott-Waldron, MSPH In the summer of 2015, a total of 3 cases of cutaneous leish- and the species was found to be L. panamensis, one of the 4 main maniasis, all male, were reported to the Department of Health species associated with progression to metastasized mucosal and Hospitals’ (DHH) Louisiana Office of Public Health (OPH). leishmaniasis in some instances. The first 2 cases to be reported were newly acquired, a 17-year- The third case to be reported in the summer of 2015 was from old male and his father, a 49-year-old male. Both had traveled to an Australian resident with an extensive travel history prior to Costa Rica approximately 2 months prior to their initial medical developing the skin lesion, although exact travel history could not consultation, and although they noticed bug bites after the trip, be confirmed. The case presented with a non-healing skin ulcer they did not notice any flies while traveling. It is not known less than 1 cm in diameter on his right leg. The ulcer had been where transmission of the parasite occurred while in Costa Rica, present for 18 months and had not previously been treated.
    [Show full text]
  • Identification and Characterization of Novel Anti-Leishmanial Compounds
    Identification and Characterization of Novel Anti-leishmanial Compounds Bilal Zulfiqar Master of Philosophy, Doctor of Pharmacy Discovery Biology Griffith Institute for Drug Discovery School of Natural Sciences Griffith University Submitted in fulfilment of the requirements of the degree of Doctor of Philosophy October 2017 ABSTRACT ABSTRACT Leishmaniasis is characterized as a parasitic disease caused by the trypanosomatid protozoan termed Leishmania. Leishmaniasis is endemic in 98 countries around the globe with increased cases of morbidity and mortality emerging each day. The mode of transmission of this disease is via the bite of a sand fly, genus Phlebotomus (Old World) and Lutzomyia (New World). The life cycle of Leishmania parasite exists between the sand fly (promastigote form) and the mammalian host (amastigote form). Leishmaniasis can be characterized as cutaneous, muco-cutaneous or visceral leishmaniasis based on clinical manifestations exhibited in infected individuals. Although leishmaniasis is treatable, it faces challenges largely due to emerging resistance and extensive toxicity for current drugs. Therapeutic efficacy varies depending upon the species, symptoms and geographical regions of the Leishmania parasite. The drug discovery pipeline for neglected trypanosomatid diseases remains sparse. In particular, the field of leishmaniasis drug discovery has had limited success in translating potential drug candidates into viable therapies. Currently there are few compounds that are clinical candidates for leishmaniasis, it is therefore essential that new compounds that are active against Leishmania are identified and evaluated for their potential to progress through the drug discovery pipeline. In order to identify new therapeutics, it is imperative that robust, biologically relevant assays be developed for the screening of anti-leishmanial compounds.
    [Show full text]
  • Ce Document Est Le Fruit D'un Long Travail Approuvé Par Le Jury De Soutenance Et Mis À Disposition De L'ensemble De La Communauté Universitaire Élargie
    AVERTISSEMENT Ce document est le fruit d'un long travail approuvé par le jury de soutenance et mis à disposition de l'ensemble de la communauté universitaire élargie. Il est soumis à la propriété intellectuelle de l'auteur. Ceci implique une obligation de citation et de référencement lors de l’utilisation de ce document. D'autre part, toute contrefaçon, plagiat, reproduction illicite encourt une poursuite pénale. Contact : [email protected] LIENS Code de la Propriété Intellectuelle. articles L 122. 4 Code de la Propriété Intellectuelle. articles L 335.2- L 335.10 http://www.cfcopies.com/V2/leg/leg_droi.php http://www.culture.gouv.fr/culture/infos-pratiques/droits/protection.htm UNIVERSITE DE LORRAINE 2018 ___________________________________________________________________________ FACULTE DE PHARMACIE THESE Présentée et soutenue publiquement Le 27 JUIN 2018, sur un sujet dédié à : LA MALADIE DE CHAGAS : DIAGNOSTIC, CLINIQUE ET PERSPECTIVES D’UNE MALADIE NÉGLIGÉE Pour obtenir Le Diplôme d'Etat de Docteur en Pharmacie Par Sébastien KAUFFMANN Né le 07/09/1988 à NANCY Membres du Jury Président : COULON JOEL, Maître de Conférences, faculté de pharmacie à Nancy Juges : BANAS SANDRINE, Maître de Conférences, faculté de pharmacie de Nancy BELLANGER XAVIER, Maître de Conférences, faculté de pharmacie de Nancy DUVAL NICOLE, Pharmacienne officinale UNIVERSITÉ DE LORRAINE FACULTÉ DE PHARMACIE Année universitaire 2017-2018 DOYEN Francine PAULUS Vice-Doyen/Directrice des études Virginie PICHON Conseil de la Pédagogie Présidente,
    [Show full text]
  • Manual for the Diagnosis and Treatment of Leishmaniasis
    Republic of the Sudan Federal Ministry of Health Communicable and Non-Communicable Diseases Control Directorate MANUAL FOR THE DIAGNOSIS AND TREATMENT OF LEISHMANIASIS November 2017 Acknowledgements The Communicable and Non-Communicable Diseases Control Directorate (CNCDCD), Federal Ministry of Health, Sudan, would like to acknowledge all the efforts spent on studying, controlling and reducing morbidity and mortality of leishmaniasis in Sudan, which culminated in the formulation of this manual in April 2004, updated in October 2014 and again in November 2017. We would like to express our thanks to all National institutions, organizations, research groups and individuals for their support, and the international organization with special thanks to WHO, MSF and UK- DFID (KalaCORE). I Preface Leishmaniasis is a major health problem in Sudan. Visceral, cutaneous and mucosal forms of leishmaniasis are endemic in various parts of the country, with serious outbreaks occurring periodically. Sudanese scientists have published many papers on the epidemiology, clinical manifestations, diagnosis and management of these complex diseases. This has resulted in a better understanding of the pathogenesis of the various forms of leishmaniasis and has led to more accurate and specific diagnostic methods and better therapy. Unfortunately, many practitioners are unaware of these developments and still rely on outdated diagnostic procedures and therapy. This document is intended to help those engaged in the diagnosis, treatment and nutrition of patients with various forms of leishmaniasis. The guidelines are based on publications and experience of Sudanese researchers and are therefore evidence based. The guidelines were agreed upon by top researchers and clinicians in workshops organized by the Leishmaniasis Control response at the Communicable and Non-Communicable Diseases Control Directorate, Federal Ministry of Health, Sudan.
    [Show full text]
  • Visceral Leishmaniasis in the Developing World
    Visceral Leishmaniasis in the Developing World Gilead Sciences is committed to supporting global efforts to control and eliminate visceral leishmaniasis (VL), a parasitic infectious disease that predominantly affects people in developing world countries. AmBisome® is a World Health Organization (WHO)-preferred treatment for VL in most endemic regions,1 and Gilead undertakes a number of activities to expand global access to this therapy for patients in need. Snapshot • Visceral leishmaniasis (VL) is • Since 1992, Gilead has • Gilead is donating the world’s second-deadliest provided AmBisome®, 445,000 vials of AmBisome parasitic disease, after malaria.1 a preferred treatment for VL, to the World Health at no-profit prices. Organization over 5 years.2 and, in a recent study in India, this regimen was shown VL: A Deadly Disease in the to be significantly more cost-effective than conventional Developing World amphotericin B-containing treatment regimens.5 VL is the world’s second-deadliest parasitic Gilead has worked since 1992 to increase access to VL disease after malaria, with 400,000 cases and treatment by providing AmBisome to public sector agencies, 40,000 deaths occuring annually.1,3 It is caused by several including WHO, at no-profit prices. In December 2011, Gilead species of the Leishmania parasite, which are transmitted signed a new agreement with WHO to donate 445,000 vials to humans through the bite of infected female sandflies. of AmBisome over five years to treat VL in countries including Without treatment, VL is nearly always fatal.3 Bangladesh, Ethiopia, South Sudan and Sudan. The donation will provide treatment for more than 50,000 patients.2 Most VL cases worldwide affect children and young adults.
    [Show full text]